Mylan Announces Tentative Approval For Venlafaxine Hydrochloride Tablets

Mylan Laboratories Inc.
(NYSE: MYL) announced that the U.S. Food and Drug Administration has
granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New
Drug Application for Venlafaxine Hydrochloride Tablets 25 mg (base), 37.5
mg (base), 50 mg (base), 75 mg (base) and 100 mg (base).


Venlafaxine HCl Tablets are indicated for the treatment of major
depressive disorder. They are the AB-rated generic version of Wyeth's
Effexor(R) Tablets, which had annual U.S. sales of approximately $154
million for the 12 months ending June 30, 2006.


Mylan Laboratories Inc. is a leading pharmaceutical company with three
principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc.
and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets
and distributes an extensive line of generic and proprietary products.


For more information about Mylan, please visit mylan/.


Mylan Laboratories Inc.

mylan/